BioLife Q3 revenue up 31%, raises 2025 guidance

BioLife Solutions

06/11/2025 21:42

Overview

BioLife Q3 2025 total revenue rises 31% yr/yr, driven by cell processing growth

Cell processing revenue increases 33% yr/yr

Company raises full-year 2025 revenue guidance to $95.0 mln - $96.0 mln

Outlook

BioLife raises 2025 Cell Processing revenue guidance to $93 mln - $94 mln

Company updates 2025 total revenue guidance to $95 mln - $96 mln

BioLife expects 2025 gross margin in low-60% range, adjusted margin mid-60%

Result Drivers

CELL PROCESSING DEMAND - Growth driven by strong demand from customers with commercially approved therapies

ACCELERATED REVENUE - Biopreservation media revenue accelerated into Q3 2025 at a commercial customer's request

BUSINESS RESTRUCTURING - Sale of evo subsidiary streamlined operations, focusing on cell processing

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Adjusted Gross Margin
64.00%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for BioLife Solutions Inc is $31.00, about 11.1% above its November 5 closing price of $27.57

Press Release: ID:nPnbxrN0va

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)